Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free CLGN Stock Alerts

CollPlant Biotechnologies (CLGN) Financials

CollPlant Biotechnologies logo
$3.50 -0.04 (-1.13%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$3.50 0.00 (-0.14%)
As of 09/11/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for CollPlant Biotechnologies

Annual Income Statements for CollPlant Biotechnologies

This table shows CollPlant Biotechnologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -73 0.00 -0.58 -6.25 -11 -5.77 0.24 -17 -7.02 -17 -11
Consolidated Net Income / (Loss)		 -73 0.00 -0.58 -6.25 -11 -5.77 0.24 -17 -7.02 -17 -11
Net Income / (Loss) Continuing Operations		 -73 0.00 -0.58 -6.43 -11 -5.77 0.24 -17 -7.02 -17 -11
Total Pre-Tax Income 		-73 0.00 -0.58 -6.43 -11 -5.77 0.24 -17 -7.02 -17 -11
Total Operating Income		 -73 0.00 -0.58 -4.25 -7.63 -5.60 0.07 -17 -7.51 -17 -11
Total Gross Profit		 0.00 0.00 0.42 3.36 0.44 3.14 14 -0.10 8.97 -1.11 1.54
Total Revenue		 0.00 0.00 0.00 5.01 2.32 6.14 16 0.30 11 0.52 2.37
Operating Revenue		 0.00 0.00 - 5.01 2.32 6.14 16 0.30 11 0.52 2.37
Total Cost of Revenue		 0.00 0.00 0.00 1.66 1.88 3.00 2.01 0.40 1.99 1.63 0.84
Operating Cost of Revenue		 0.00 0.00 - 1.66 1.88 3.00 2.01 0.40 1.99 1.63 0.84
Total Operating Expenses		 73 0.00 0.58 7.60 8.07 8.73 14 17 16 16 13
Selling, General & Admin Expense		 27 0.00 - 3.72 3.66 4.67 5.94 6.74 6.00 5.63 4.83
Research & Development Expense		 46 0.00 0.58 3.88 4.41 4.07 7.63 10 10 11 8.19
Total Other Income / (Expense), net		 0.64 0.00 0.00 -2.18 -3.53 -0.18 0.17 0.17 0.49 0.64 -0.01
Other Income / (Expense), net		 - - - -2.18 -3.53 -0.18 0.17 0.17 0.49 0.64 -0.01
Basic Earnings per Share		 $0.22 - - $1.43 ($2.23) ($0.84) $0.02 ($1.53) ($0.62) ($1.45) ($0.94)
Weighted Average Basic Shares Outstanding		 84.67M 100.62M 2.66M 4.38M 4.99M 6.89M 9.97M 11.03M 11.39M 11.45M 12.20M
Diluted Earnings per Share		 $0.22 - - $1.43 ($2.23) ($0.84) $0.02 ($1.53) ($0.62) ($1.45) ($0.94)
Weighted Average Diluted Shares Outstanding		 84.67M 100.62M 2.66M 4.38M 4.99M 6.89M 11.97M 11.03M 11.39M 11.45M 12.20M
Weighted Average Basic & Diluted Shares Outstanding		 84.67M 100.62M 2.66M 4.38M 4.99M 6.89M 10.77M 11.19M 11.45M 11.45M 12.80M

Quarterly Income Statements for CollPlant Biotechnologies

No quarterly income statements for CollPlant Biotechnologies are available.

Annual Cash Flow Statements for CollPlant Biotechnologies

This table details how cash moves in and out of CollPlant Biotechnologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -23 0.00 4.01 -0.20 8.11 -0.45 9.85 16 -3.19 -15 -6.32
Net Cash From Operating Activities		 -57 0.00 -4.97 -1.22 -5.70 -4.45 2.50 -14 -2.76 -14 -9.42
Net Cash From Continuing Operating Activities		 -59 0.00 -4.46 -2.13 4.16 -4.45 2.50 -14 -3.14 -14 -9.34
Net Income / (Loss) Continuing Operations		 -73 0.00 -6.05 -6.25 0.00 -5.77 0.24 -17 -7.02 -17 -11
Consolidated Net Income / (Loss)		 -73 0.00 -6.05 -6.25 - -5.77 0.24 -17 -7.02 -17 -11
Depreciation Expense		 3.07 0.00 0.23 0.34 0.54 0.66 0.77 1.08 1.10 1.04 0.91
Non-Cash Adjustments To Reconcile Net Income		 16 0.00 0.96 3.85 3.23 1.57 1.28 2.09 1.93 1.85 0.98
Changes in Operating Assets and Liabilities, net		 -5.71 0.00 0.40 -0.07 0.39 -0.91 0.22 -0.54 0.85 -0.37 0.25
Net Cash From Investing Activities		 -5.42 0.00 -0.13 -0.83 -1.46 -0.52 -32 29 -1.16 -0.54 -0.03
Net Cash From Continuing Investing Activities		 -5.42 0.00 -0.13 -0.83 -1.46 -0.52 -32 29 -1.16 -0.54 -0.03
Purchase of Property, Plant & Equipment		 -5.42 0.00 -0.13 -0.83 -1.49 -0.44 -1.43 -1.27 -0.95 -0.48 -0.03
Sale of Property, Plant & Equipment		 - - 0.00 0.00 0.03 0.00 0.03 0.00 0.07 0.00 0.00
Other Investing Activities, net		 - - - - - 0.00 0.00 0.00 -0.27 -0.06 0.00
Net Cash From Financing Activities		 39 0.00 9.11 2.75 5.41 4.47 39 1.87 1.11 0.01 3.10
Net Cash From Continuing Financing Activities		 39 0.00 9.11 2.75 5.41 4.47 39 1.87 1.11 0.01 3.10
Issuance of Common Equity		 39 0.00 8.15 - 0.00 - 33 - 0.00 0.00 3.10
Other Financing Activities, net		 0.11 0.00 1.02 -0.07 -0.01 0.09 6.02 1.87 1.11 0.01 0.00
Cash Income Taxes Paid		 - - - - - 0.00 0.00 0.03 0.01 0.06 0.02

Quarterly Cash Flow Statements for CollPlant Biotechnologies

No quarterly cash flow statements for CollPlant Biotechnologies are available.

Annual Balance Sheets for CollPlant Biotechnologies

This table presents CollPlant Biotechnologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 55 0.00 8.75 11 11 51 38 34 19 11
Total Current Assets		 31 4.75 7.02 5.04 5.68 45 32 28 13 6.75
Cash & Equivalents		 15 4.75 5.35 3.79 3.33 13 30 27 12 5.59
Restricted Cash		 - - - 0.01 0.01 0.01 0.02 0.24 0.25 0.36
Accounts Receivable		 15 0.00 0.85 0.08 0.83 0.27 0.01 0.00 0.15 0.00
Inventories, net		 1.87 0.00 0.81 0.89 1.26 1.08 1.43 0.71 0.44 0.57
Prepaid Expenses		 - - - 0.27 0.24 0.42 0.54 0.39 0.43 0.22
Plant, Property, & Equipment, net		 15 0.00 1.41 2.33 2.11 2.73 2.97 2.79 2.29 1.46
Total Noncurrent Assets		 6.27 0.00 0.33 3.38 3.06 34 3.14 3.32 3.24 2.58
Long-Term Investments		 - - - - - - 0.19 0.06 0.12 0.08
Intangible Assets		 6.27 0.00 - 0.00 0.08 0.24 0.25 0.19 0.13 0.07
Other Noncurrent Operating Assets		 - 0.00 0.31 3.38 2.98 33 2.71 3.07 2.99 2.43
Total Liabilities & Shareholders' Equity		 55 0.00 7.77 11 11 51 38 34 19 11
Total Liabilities		 36 0.00 3.33 6.66 6.36 6.10 5.49 5.79 5.25 4.70
Total Current Liabilities		 26 0.00 1.24 3.46 3.39 3.01 3.11 3.25 2.97 2.67
Accounts Payable		 26 0.00 0.62 0.83 0.80 1.03 1.13 0.98 0.87 0.61
Accrued Expenses		 - 0.00 0.62 1.20 1.94 1.43 1.44 1.65 1.29 1.25
Other Current Liabilities		 - 0.00 - 0.46 0.44 0.52 0.53 0.62 0.81 0.81
Total Noncurrent Liabilities		 0.00 0.00 0.14 3.21 2.98 3.09 2.38 2.54 2.28 2.03
Other Noncurrent Operating Liabilities		 0.00 0.00 0.10 3.21 2.98 3.09 2.38 2.54 2.28 2.03
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 20 0.00 6.39 4.09 4.48 45 32 28 13 6.08
Total Preferred & Common Equity		 20 0.00 6.39 4.09 4.48 45 32 28 13 6.08
Total Common Equity		 20 0.00 6.39 4.09 4.48 45 32 28 13 6.08
Common Stock		 627 0.00 1.58 72 78 119 123 126 128 132
Retained Earnings		 -607 0.00 -56 -67 -73 -73 -90 -97 -113 -125
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - -0.97 -0.97 -0.97 -0.97

Quarterly Balance Sheets for CollPlant Biotechnologies

No quarterly balance sheets for CollPlant Biotechnologies are available.

Annual Metrics And Ratios for CollPlant Biotechnologies

This table displays calculated financial ratios and metrics derived from CollPlant Biotechnologies' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 166,816,287.00 190,735,668.00 5,670,829.00 6,963,838.00 10,772,024.00 11,186,481.00 11,452,672.00 11,452,672.00 11,452,672.00
DEI Adjusted Shares Outstanding		 0.00 0.00 3,336,326.00 3,814,713.00 5,670,829.00 6,963,838.00 10,772,024.00 11,186,481.00 11,452,672.00 11,452,672.00 11,452,672.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.18 -1.64 -1.97 -0.83 0.02 -1.51 -0.61 -1.45 -1.00
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -51 0.00 -0.41 -2.97 -5.34 -3.92 0.07 -12 -5.26 -12 -8.04
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -37.07% -18.55% -89.68% -132.18%
Earnings before Interest and Taxes (EBIT)		 -73 0.00 -0.58 -6.43 -11 -5.77 0.24 -17 -7.02 -17 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -70 0.00 -0.35 -6.08 -11 -5.11 1.01 -16 -5.92 -16 -11
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -12 12 -5.03 -3.59 -4.74 -31 18 -4.21 -12 -6.90
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 12 0.00 2.06 0.31 1.13 32 2.42 1.37 1.19 0.06
Increase / (Decrease) in Invested Capital		 0.00 12 -12 2.06 -1.75 0.82 31 -30 -1.05 -0.18 -1.14
Book Value per Share		 $0.00 $0.20 $0.00 $0.04 $0.02 $0.79 $6.48 $3.00 $2.53 $1.18 $0.50
Tangible Book Value per Share		 $0.00 $0.13 $0.00 $0.04 $0.02 $0.78 $6.44 $2.97 $2.52 $1.16 $0.49
Total Capital		 0.00 20 0.00 6.43 4.11 4.48 45 32 28 13 6.08
Total Debt		 0.00 0.00 0.00 0.04 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -15 -4.75 -5.31 -3.78 -3.35 -13 -30 -27 -12 -6.03
Capital Expenditures (CapEx)		 5.42 0.00 0.13 0.83 1.46 0.44 1.40 1.27 0.89 0.48 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -9.74 0.00 0.42 -2.20 -1.06 29 -1.12 -2.14 -1.95 -1.88
Debt-free Net Working Capital (DFNWC)		 0.00 4.86 4.75 5.78 1.61 2.29 42 29 25 10 4.08
Net Working Capital (NWC)		 0.00 4.86 4.75 5.78 1.58 2.29 42 29 25 10 4.08
Net Nonoperating Expense (NNE)		 21 0.00 0.18 3.28 5.82 1.85 -0.17 4.96 1.76 4.53 3.45
Net Nonoperating Obligations (NNO)		 0.00 -7.90 0.00 -4.33 -3.78 -3.35 -13 -30 -27 -12 -6.03
Total Depreciation and Amortization (D&A)		 3.07 0.00 0.23 0.34 0.54 0.66 0.77 1.08 1.10 1.04 0.91
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $8.00 $3.00 $0.00 $0.84 $0.02 ($1.53) ($0.62) ($1.45) ($0.94)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 3.34M 3.81M 5.67M 6.96M 9.97M 11.03M 11.39M 11.45M 12.20M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $8.00 $3.00 $0.00 $0.84 $0.02 ($1.53) ($0.62) ($1.45) ($0.94)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 3.34M 3.81M 5.67M 6.96M 11.97M 11.03M 11.39M 11.45M 12.20M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $8.00 $3.00 $0.00 $0.84 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 2.66M 4.38M 4.99M 6.89M 10.77M 11.19M 11.45M 11.45M 12.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -51 0.00 -0.41 -2.97 -5.34 -3.92 0.05 -12 -5.26 -12 -8.04
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for CollPlant Biotechnologies

No quarterly metrics and ratios for CollPlant Biotechnologies are available.


Financials Breakdown Chart

CollPlant Biotechnologies Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CollPlant Biotechnologies' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

CollPlant Biotechnologies' net income appears to be on a downward trend, with a most recent value of -$11.49 million in 2025, falling from -$72.77 million in 2015. The previous period was -$16.61 million in 2024. See CollPlant Biotechnologies' forecast for analyst expectations on what's next for the company.

CollPlant Biotechnologies' total operating income in 2025 was -$11.48 million, based on the following breakdown:
  • Total Gross Profit: $1.54 million
  • Total Operating Expenses: $13.02 million

Over the last 10 years, CollPlant Biotechnologies' total revenue changed from $0.00 in 2015 to $2.37 million in 2025, a change of 237,100,000.0%.

CollPlant Biotechnologies' total liabilities were at $4.70 million at the end of 2025, a 10.3% decrease from 2024, and a 86.8% decrease since 2016.

In the past 9 years, CollPlant Biotechnologies' cash and equivalents has ranged from $3.33 million in 2020 to $29.65 million in 2022, and is currently $5.59 million as of their latest financial filing in 2025.

Over the last 10 years, CollPlant Biotechnologies' book value per share changed from 0.00 in 2015 to 0.50 in 2025, a change of 49.8%.


Related Companies

Financial statements for NASDAQ:CLGN last updated on 8/31/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel